Teleflex Inc
TFX NYSE Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
What Teleflex Inc does
No business description yet.
- Legal name
- TELEFLEX INC
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 27, 2026
- Accession Β· CIK
- 0000096943-26-000019
0000096943
Revenue and margins
Teleflex Inc had $2.0B of revenue in fiscal 2025, up 17.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $1.4M in fiscal 2025, 0.1% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Teleflex Inc returned $360M to shareholders in fiscal 2025, 24,915% of free cash flow. The diluted share count fell 5.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Teleflex Inc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $445M | $292M | $223M | $248M | $379M |
| Debt incl. finance leases | $2.0B | $1.8B | $1.9B | $1.8B | $2.7B |
| Net debt / EBITDA | 1.8x | 2.1x | 4.1x | 5.7x | 8.0x |
| Debt / equity | 0.5x | 0.4x | 0.4x | 0.4x | 0.9x |
| Interest coverage | 11.0x | 9.2x | 3.0x | 1.2x | 1.2x |
| Current ratio | 2.1x | 2.4x | 2.3x | 2.3x | 2.5x |
| Quick ratio | 1.4x | 1.4x | 1.3x | 1.8x | 2.0x |
| Total assets | $6.9B | $6.9B | $7.5B | $7.1B | $6.9B |
| Total liabilities | $3.1B | $2.9B | $3.1B | $2.8B | $3.8B |
| Shareholders' equity | $3.8B | $4.0B | $4.4B | $4.3B | $3.1B |
| Net debt (β = net cash) | $1.5B | $1.5B | $1.7B | $1.5B | $2.4B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 6 / 9 | 7 / 9 | 4 / 9 | 7 / 9 | 5 / 9 | 5 / 9 | 7 / 9 | 5 / 9 |
| Accruals ratio | β4.5% | β5.4% | β3.8% | 0.4% | β1.5% | β2.4% | 0.3% | 2.1% | β3.2% | β14.3% |
| Altman Z'' | 4.95 | 2.98 | 3.00 | 3.63 | 3.54 | 4.26 | 4.52 | 4.22 | 4.34 | 3.56 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.9B | $2.1B | $2.4B | $2.6B | $2.5B | $2.8B | $2.8B | $1.7B | $1.7B | $2.0B |
| Gross profit | $996M | $1.2B | $1.3B | $1.4B | $1.3B | $1.5B | $1.5B | $1.0B | $1.0B | $1.1B |
| Research and development | $58.6M | $84.8M | $106M | $114M | $120M | $131M | $154M | $114M | $109M | $145M |
| Operating income | $319M | $372M | $322M | $427M | $423M | $628M | $500M | $259M | $104M | $118M |
| Interest expense | $54.9M | $82.5M | $103M | $80.3M | $66.5M | $57.0M | $54.3M | $85.1M | $83.5M | $100M |
| Pretax income | $246M | $285M | $220M | $340M | $358M | $559M | $446M | $185M | $26.3M | $24.6M |
| Income tax | $8.1M | $130M | $23.2M | β$122M | $21.9M | $74.3M | $83.0M | $41.9M | β$30.9M | β$34.0M |
| Net income | $237M | $153M | $201M | $461M | $335M | $485M | $363M | $356M | $69.7M | β$906M |
| Diluted EPS | $4.98 | $3.27 | $4.29 | $9.80 | $7.09 | $10.23 | $7.68 | $7.53 | $1.48 | β$20.25 |
| Diluted shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | $411M | $426M | $435M | $437M | $437M | $652M | $343M | $206M | $302M | $96.7M |
| Capital expenditure | $53.1M | $70.9M | $80.8M | $103M | $90.7M | $71.6M | $79.2M | $46.4M | $90.4M | $95.2M |
| Free cash flow | $357M | $355M | $354M | $334M | $346M | $581M | $264M | $160M | $211M | $1.4M |
| Depreciation and amortization | $128M | $160M | $215M | $218M | $227M | $237M | $231M | $148M | $162M | $178M |
| Stock-based compensation | $16.9M | $19.4M | $22.4M | $26.9M | $20.7M | $22.9M | $27.2M | $27.3M | $26.0M | $25.7M |
| Share buybacks | β | β | β | β | β | β | $0.0M | $0.0M | $200M | $300M |
| Dividends paid | $59.0M | $61.2M | $62.2M | $62.8M | $63.2M | $63.6M | $63.8M | $63.9M | $63.5M | $60.3M |
| Dividends and buybacks | $59.0M | $61.2M | $62.2M | $62.8M | $63.2M | $63.6M | $63.8M | $63.9M | $264M | $360M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $544M | $334M | $357M | $301M | $376M | $445M | $292M | $223M | $248M | $379M |
| Total debt | $1.2B | $2.3B | $2.2B | $2.0B | $2.6B | $2.0B | $1.8B | $1.9B | $1.8B | $2.7B |
| Current assets | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.9B |
| Current liabilities | $428M | $484M | $582M | $563M | $540M | $680M | $581M | $607M | $649M | $762M |
| Inventory | $316M | $396M | $428M | $477M | $513M | $478M | $579M | $626M | $307M | $404M |
| Property and equipment, net | $303M | $383M | $433M | $431M | $474M | $444M | $447M | $480M | $308M | $498M |
| Goodwill | $1.3B | $2.2B | $2.2B | $2.2B | $2.6B | $2.5B | $2.5B | $2.9B | $2.0B | $2.3B |
| Intangible assets | $1.1B | $2.4B | $2.3B | $2.2B | $2.5B | $2.3B | $2.3B | $2.5B | $1.3B | $1.5B |
| Total assets | $3.9B | $6.2B | $6.3B | $6.3B | $7.2B | $6.9B | $6.9B | $7.5B | $7.1B | $6.9B |
| Total liabilities | $1.8B | $3.8B | $3.7B | $3.3B | $3.8B | $3.1B | $2.9B | $3.1B | $2.8B | $3.8B |
| Shareholders' equity | $2.1B | $2.4B | $2.5B | $3.0B | $3.3B | $3.8B | $4.0B | $4.4B | $4.3B | $3.1B |
| Margins | ||||||||||
| Gross margin | 53.3% | 54.6% | 53.2% | 54.3% | 52.2% | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% |
| Operating margin | 17.1% | 17.3% | 13.1% | 16.5% | 16.7% | 22.4% | 17.9% | 15.1% | 6.1% | 5.9% |
| EBITDA margin | 24.0% | 24.8% | 21.9% | 24.9% | 25.6% | 30.8% | 26.2% | 23.8% | 15.6% | 14.9% |
| Net margin | 12.7% | 7.1% | 8.2% | 17.8% | 13.2% | 17.3% | 13.0% | 20.8% | 4.1% | β45.4% |
| FCF margin | 19.1% | 16.6% | 14.5% | 12.9% | 13.7% | 20.7% | 9.4% | 9.3% | 12.4% | 0.1% |
| Returns | ||||||||||
| Return on capital | 11.0% | 5.5% | 6.5% | 9.2% | 7.2% | 10.3% | 7.4% | 3.3% | 1.8% | 2.2% |
| Return on capital employed | 9.2% | 6.5% | 5.6% | 7.4% | 6.4% | 10.1% | 7.9% | 3.7% | 1.6% | 1.9% |
| Return on equity | 11.1% | 6.7% | 8.1% | 16.7% | 10.6% | 13.7% | 9.3% | 8.4% | 1.6% | β24.5% |
| Return on assets | 6.1% | 3.0% | 3.2% | 7.3% | 5.0% | 6.9% | 5.3% | 4.9% | 1.0% | β12.9% |
| Return on tangible equity | β | β | β | β | β | β | β | β | 7.4% | β |
| Growth | ||||||||||
| Revenue growth | β | 14.9% | 14.1% | 6.0% | β2.2% | 10.7% | β0.7% | β38.6% | β0.8% | 17.2% |
| Net income growth | β | β35.7% | 31.6% | 129.8% | β27.3% | 44.7% | β25.2% | β1.9% | β80.4% | β1,399.8% |
| EPS growth | β | β34.3% | 31.2% | 128.4% | β27.7% | 44.3% | β24.9% | β2.0% | β80.3% | β1,468.2% |
| FCF growth | β | β0.6% | β0.3% | β5.6% | 3.6% | 67.6% | β54.6% | β39.4% | 32.4% | β99.3% |
| Share count change | β | β2.1% | 0.3% | 0.6% | 0.4% | 0.3% | β0.2% | β0.0% | β0.4% | β5.0% |
| Financial health | ||||||||||
| Net debt / EBITDA | 1.5x | 3.8x | 3.5x | 2.6x | 3.4x | 1.8x | 2.1x | 4.1x | 5.7x | 8.0x |
| Debt / equity | 0.6x | 1.0x | 0.9x | 0.7x | 0.8x | 0.5x | 0.4x | 0.4x | 0.4x | 0.9x |
| Interest coverage | 5.8x | 4.5x | 3.1x | 5.3x | 6.4x | 11.0x | 9.2x | 3.0x | 1.2x | 1.2x |
| Current ratio | 2.8x | 2.3x | 2.1x | 2.3x | 2.6x | 2.1x | 2.4x | 2.3x | 2.3x | 2.5x |
| Quick ratio | 2.0x | 1.5x | 1.4x | 1.5x | 1.7x | 1.4x | 1.4x | 1.3x | 1.8x | 2.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.8% | 3.3% | 3.3% | 4.0% | 3.6% | 2.5% | 2.8% | 2.7% | 5.3% | 4.8% |
| Stock comp / revenue | 0.9% | 0.9% | 0.9% | 1.0% | 0.8% | 0.8% | 1.0% | 1.6% | 1.5% | 1.3% |
| Payouts / FCF | 16.5% | 17.2% | 17.5% | 18.8% | 18.2% | 11.0% | 24.2% | 40.0% | 124.6% | 24,914.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 6.0 | 7.0 | 4.0 | 7.0 | 5.0 | 5.0 | 7.0 | 5.0 |
| Altman Z'' | 4.9 | 3.0 | 3.0 | 3.6 | 3.5 | 4.3 | 4.5 | 4.2 | 4.3 | 3.6 |
| Accruals ratio | β4.5% | β5.4% | β3.8% | 0.4% | β1.5% | β2.4% | 0.3% | 2.1% | β3.2% | β14.3% |
Source: SEC EDGAR XBRL filings (CIK 0000096943). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.